OAM
ABVX

Oppenheimer Asset Management’s Abivax ABVX Stock Holding History

Oppenheimer Asset Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$501K Buy
4,496
+115
+3% +$13.6K 0.01% 868
2025
Q4 		$591K Buy
4,381
+1,280
+41% +$140K 0.01% 781
2025
Q3 		$263K Buy
+3,101
New +$190K ﹤0.01% 1034

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Oppenheimer Asset Management's ABVX Position: Q1 2026 in Review

Oppenheimer Asset Management increased its Abivax (ABVX) stake by 2.6% in Q1 2026, buying an estimated $13.6K and bringing the position to 4,496 shares worth $501K. The position accounts for 0.01% of the portfolio, ranked #868.

Oppenheimer Asset Management first reported a position in ABVX in Q3 2025 and has held it in 3 quarters since. The position peaked at $591K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Oppenheimer Asset Management held 4,496 shares of Abivax worth $501K as of Q1 2026.
  • Oppenheimer Asset Management bought 115 Abivax shares in Q1 2026, an estimated $13.6K.
  • Abivax made up 0.01% of Oppenheimer Asset Management's portfolio in Q1 2026, its #868 holding.
  • Oppenheimer Asset Management first reported a position in Abivax in Q3 2025 and has held it in 3 quarters since.
  • Oppenheimer Asset Management's Abivax position peaked at $591K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.